Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

107.67 +0.04 (+0.04%)
Streaming Delayed Price Updated: 2:42 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Investors Like Certainty. Trump's Win Gave Them Some.
We're also talking about Super Micro, Nvidia, and weight loss. 
Via The Motley Fool
Topics Government
Exposures Political
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve... 
Via Benzinga
Topics Death
Exposures Death Product Safety
Novo Nordisk Aims For The Top: CagriSema Poised For Breakthrough
Novo Nordisk is positioning its new obesity drug, CagriSema, to potentially lead to at least 25% weight loss in patients, setting a new benchmark in the competitive weight-loss drug market. 
Via Talk Markets
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
Via Benzinga
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but falls short of analyst expectations. 
Via Benzinga
How Is The Market Feeling About Novo Nordisk?
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses
The company also tightened its sales outlook for the year. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date. 
Via Benzinga
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock jumped late Monday after the online pharmacy beat expectations. 
Via Investor's Business Daily
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. 
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,... 
Via Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making any guarantees. 
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
The biotech reported strong weight loss for higher doses of its experimental obesity pill. 
Via Investor's Business Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects. 
Via The Motley Fool
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. 
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
Via Benzinga
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
Via MarketBeat
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
Exposures Product Safety
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
To gain an edge, this is what you need to know today. 
Via Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. 
Via The Motley Fool
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.